Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,652
  • Shares Outstanding, K 27,533
  • Annual Sales, $ 34,050 K
  • Annual Income, $ -131,000 K
  • 60-Month Beta 1.53
  • Price/Sales 3.72
  • Price/Cash Flow N/A
  • Price/Book 1.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.97
  • Number of Estimates 5
  • High Estimate -0.82
  • Low Estimate -1.10
  • Prior Year -1.26
  • Growth Rate Est. (year over year) +23.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +8.10%
on 06/12/19
6.41 -29.17%
on 05/16/19
-0.95 (-17.30%)
since 05/14/19
3-Month
4.20 +8.10%
on 06/12/19
8.25 -44.97%
on 03/20/19
-3.36 (-42.53%)
since 03/14/19
52-Week
4.20 +8.10%
on 06/12/19
29.49 -84.60%
on 08/03/18
-22.93 (-83.47%)
since 06/14/18

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ADMS : 4.54 (-1.30%)
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals,...

ADMS : 4.54 (-1.30%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 148,500...

ADMS : 4.54 (-1.30%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ:...

ADMS : 4.54 (-1.30%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ADMS : 4.54 (-1.30%)
Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar,...

ADMS : 4.54 (-1.30%)
Relatively Good Performance Detected in Shares of Biomarin Pharmac in the Biotechnology Industry (BMRN , VCYT , ADMS , RTRX , EXAS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

VCYT : 27.57 (-1.29%)
ADMS : 4.54 (-1.30%)
BMRN : 80.84 (-1.85%)
Adamas (ADMS) Upgraded to Buy: Here's Why

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADMS : 4.54 (-1.30%)
Adamas to Present at Upcoming BAML Investor Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D.,...

ADMS : 4.54 (-1.30%)
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Lags Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMS : 4.54 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADMS with:

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

2nd Resistance Point 4.89
1st Resistance Point 4.71
Last Price 4.54
1st Support Level 4.44
2nd Support Level 4.35

See More

52-Week High 29.49
Fibonacci 61.8% 19.83
Fibonacci 50% 16.84
Fibonacci 38.2% 13.86
Last Price 4.54
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar